Fulton-Kehoe D, Rossing M A, Rutter C, Mandelson M T, Weiss N S
Department of Environmental and Occupational Health Sciences, University of Washington, School of Public Health and Community Medicine, Seattle, WA, USA.
Br J Cancer. 2006 Apr 10;94(7):1071-8. doi: 10.1038/sj.bjc.6603017.
Although associations have been reported between antidepressant use and risk of breast cancer, the findings have been inconsistent. We conducted a population-based case-control study among women enrolled in Group Health Cooperative (GHC), a health maintenance organization in Washington State. Women with a first primary breast cancer diagnosed between 1990 and 2001 were identified (N = 2904) and five controls were selected for each case (N = 14396). Information on antidepressant use was ascertained through the GHC pharmacy database and on breast cancer risk factors and screening mammograms from GHC records. Prior to one year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio = 1.06, 95% CI 0.94-1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR = 0.98, 95% CI 0.80-1.18). There also were no differences between cases and controls with regard to the number of prescriptions filled or the timing of use. Taken as a whole, the results from this and other studies to date do not indicate an altered risk of breast cancer associated with the use of antidepressants overall, by class, or for individual antidepressants.
虽然已有报告称抗抑郁药的使用与乳腺癌风险之间存在关联，但研究结果并不一致。我们在华盛顿州的一家健康维护组织——Group Health Cooperative（GHC）登记的女性中开展了一项基于人群的病例对照研究。确定了1990年至2001年间首次诊断为原发性乳腺癌的女性（N = 2904），并为每个病例选择了5名对照（N = 14396）。通过GHC药房数据库确定抗抑郁药使用情况，并从GHC记录中获取乳腺癌风险因素和乳腺钼靶筛查信息。在乳腺癌诊断前一年，约20%的病例和对照使用过三环类抗抑郁药（调整比值比 = 1.06，95%可信区间0.94 - 1.19），每组6%的人使用过选择性5-羟色胺再摄取抑制剂（OR = 0.98，95%可信区间0.80 - 1.18）。病例组和对照组在处方数量或用药时间方面也没有差异。总体而言，该研究及迄今为止其他研究的结果并未表明总体上、按类别或个别抗抑郁药的使用与乳腺癌风险改变有关。
